Lung Cancer: Evolution in the Treatment of NSCLC
Expert Perspectives
Expert Perspectives

Lung Cancer: Evolution in the Treatment of NSCLC

Not a member of My prIME? Join now for instant access.

Expand your knowledge of lung cancer with this discussion featuring Julie Brahmer, MD, Shirish Gadgeel, MD, Raja Mudad, MD, FACP, and David Spigel, MD. This expert faculty explores the latest information on immunotherapy, targeted therapy, chemotherapy, and practical considerations for patient management.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



1.0 AMA PRA Category 1 Credits



1.0 Contact Hour

Release Date

Release Date

Sep 29, 2017

Expiration Date

Sep 29, 2018


  • Raja Mudad, MD, FACPSylvester Comprehensive Cancer Center
    Hollywood, Florida, United States


  • Julie Brahmer, MDSidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland, United States
  • Shirish Gadgeel, MDUniversity of Michigan
    Ann Arbor, Michigan, United States
  • David Spigel, MDSarah Cannon Research Institute
    Nashville, Tennessee, United States
  • Updates in immunotherapy for non-small cell lung cancer (NSCLC)
  • Updates in targeted therapy for NSCLC
  • Patients with no driver mutation or who are ineligible for immunotherapy
  • Practical considerations for therapeutic strategies

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, nurses,  pulmonologists, pathologists, and other healthcare professionals involved in the treatment of patients with lung cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess treatment options for first and subsequent lines of therapy for NSCLC
  • Evaluate recent data in lung cancer that have the potential to impact practice, including immune checkpoint inhibitors, targeted agents, and other strategies
  • Identify strategies for the mitigation and management of adverse events associated with immunotherapy and targeted agents

This activity was developed in collaboration with the Addario Lung Cancer Foundation.

This educational activity is supported by grants from Bristol-Myers Squibb; Celgene Corporation; Lilly USA, LLC; and Merck and Co, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Lung Cancer: Evolution in the Treatment of NSCLC - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center’s COA.

A maximum of 1.0 contact hour may be earned for successful completion of this program. The criteria for successful completion include attending the full program and completing the evaluation.

Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation’s Independent Learning Needs Assessment (ILNA) renewal method. Visit for complete details on oncology nursing certification.


This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

A link to the posttest is available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Brahmer has disclosed that she has received consulting fees from Bristol-Myers Squibb (uncompensated), Celgene Corporation, Lilly, and Merck. She has also performed contracted research for Bristol-Myers Squibb, MedImmune/AstraZeneca, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.

Dr Mudad has disclosed that he has received consulting fees from Celgene Corporation. He also received fees for participation in advisory board or review activities from Genentech and Guardant Health. He has received provision of writing assistance, medicine, equipment, or administrative support from Cardinal Health and Celgene Corporation. He has received payment for development of educational materials, presentations or manuscripts from Celgene Corporation. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Gadgeel has disclosed that he has received support for travel to meetings from Genentech/Roche. He has also received research funding from ARIAD/Takeda and AstraZeneca. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Spigel has disclosed that he has received consulting fees on behalf of his institution from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Genentech/Roche, Lilly, Novartis, and Pfizer. He also disclosed receipt of research funding to his institution from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Daiichi Sankyo, Genentech/Roche, Lilly, Merck, Novartis, Oncogenex, OncoMed, Peregrine Pharmaceuticals, Pfizer, and Verastem. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Brooke Balun, MSN, APRN-BC, AOCNP (lead nurse planner) – no relevant financial relationships
  • Christi Gray (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.